Conformis, Inc. (CFMS) stock prices were up 7.62% as of market trading closing on July 16th, 2021, bringing the price per share up to USD$1.13 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 6.19%, bringing it up to USD$1.23.
Settlement Agreement
July 7th, 2021 saw the company announce having entered into a settlement agreement with Stryker Corp., thus putting to rest ongoing patent litigation in regard to Wright Medican Technology and Tornier, which were acquired by Stryker in November of 2020. The resolution of the patent litigation over the Wright Medical dispute signals the strength and value of the company’s intellectual property, as well as their unwavering commitment.
Details of the Lawsuit
April 24th, 2020 had seen CFMS file a lawsuit against Wright Medical in the United States District Court for in Delaware. The lawsuit alleged that the defendant’s various lines of patient-specific shoulder instruments infringed existing patents, as did implant components used in conjunction with the instruments. As per the terms of the settlement agreement, Stryker is set to make a one-time payment to CFMS, which will grant it a non-exclusive license for some of the company’s patents.
Distribution Agreement
June 23rd, 2021 had seen the company announce the execution of an agreement with XR Medical Group, which would see the company enter the Asia-Pacific market through an exclusive distribution relationship. As per the distribution agreement, XR Medical will be granted exclusive rights for the sale, marketing, and distribution of CFMS’ patient-specific iTotal CR and PS total knee replacement systems. Also included in the agreement are the iTotal CR and PS patella devices, as well as the iUni and iDuo partial knee replacement systems. The agreement also allows for the proactive additional of CFMS’s expanding product portfolio into the terms of the agreement.
Scope of Market
With the global market for knee joint reconstruction being pegged in excess of USD$9 billion, the Asia-Pacific region makes up an estimated USD$1.7 billion of the burgeoning marketspace. The company is keen to see the fruition of Fortune Business Insights’ forecasts of continued increases in the rate of growth, stemming largely from an increased prevalence of knee disorders, surges in medical tourism, higher disposal incomes, as well as improved healthcare infrastructure.
Future Outlook for CFMS
Armed with the resolution to their litigation issues, the company is poised to allocate its resources towards penetrating the newly accessed Asia-Pacific market. CFMS is keen to push for the continued commercialization and increased proliferation of its myriad of treatment options. Investors are hopeful that management will be able to usher in significant and sustained increases in shareholder value over the long term.
